-
The "14th Five-Year Plan" of drug supervision network security and information construction
Time of Update: 2022-08-15
5 key tasks, including promoting the integration and driving of regulatory data, consolidating the digital base for intelligent drug supervision, and consolidating the comprehensive security capability of network security The State Food and Drug Administration officially issued the "14th Five-Year Plan" (hereinafter referred to as the "Plan") for the construction of drug regulatory network security and informatization, which clearly proposes to upgrade the "two products and one machine" smart supervision capabilities and improve the integration of government services.
-
The development of the domestic innovative drug industry is accelerating, and the pharmaceutical machine industry is ushering in abundant development opportunities
Time of Update: 2022-08-15
. For example, at the end of last year, Canaan Technology stated on the investor interaction platform that the company's current business segment includes innovative pharmaceutical water equipment for biological preparations and pharmaceutical liquid dispensing system engineering business; in the future, the company will rely on pharmaceutical water equipment and pharmaceutical liquid dispensing system business.
-
The pharmaceutical sector of Hong Kong stocks rose, BeiGene rose more than 11%, and many stocks rose more than 5%
Time of Update: 2022-08-15
4. 063 billion yuan The semi-annual report shows that in the first half of this year, the company achieved a total operating income of 4.
5 million, a 120% increase from the same period a year earlier In the second quarter alone, product revenue reached $304.
-
To seize the blue ocean of traditional Chinese medicine, traditional Chinese medicine pharmaceutical equipment needs to take the road of independent innovation
Time of Update: 2022-08-15
. In recent years, as domestic pharmaceutical machine companies continue to increase research and development and explore the road of innovation, they have gradually developed from a single product to a complete set of equipment, and from a single device to providing a complete set of technical solutions, providing a strong support for the high-quality development of traditional Chinese medicine enterprises.
-
Next week, Purui Ophthalmology and Fuyuan Pharmaceutical will subscribe for two new pharmaceutical shares
Time of Update: 2022-08-15
[Pharmaceutical Network Pharmaceutical Stock Market] The listing of new stocks has always attracted the attention of the industry. This week, a total of 11 new stocks were listed, including State Cab
-
The demand for capacity expansion and efficiency enhancement of pharmaceutical companies continues to grow, and pharmaceutical equipment companies will usher in new opportunities for development
Time of Update: 2022-08-15
Trend, continue to meet the needs of pharmaceutical companies In this context, for pharmaceutical machine companies, if they want to seize the development opportunities, they must follow the industry closely by strengthening the research and development of intelligent products and moving towards a path of mechanical automation, unmanned operation, higher added value and more innovation.
-
Since the beginning of 2022, 24 pharmaceutical stocks have risen by more than 20%
Time of Update: 2022-08-15
The stock is also a stock that has outperformed the broader market in the past month, with a cumulative turnover rate of over 30% in the past 5 days Xinhua Pharma: Range rose over 155% Xinhua Pharma's share price rose over 155% from January 4 to June 22.
-
Focusing on the post-centralized procurement era, how should pharmaceutical companies respond?
Time of Update: 2022-08-15
power and market position For pharmaceutical companies, by exchanging price for volume, sales expenses can be greatly reduced, and the saved costs can be focused on the research and development of innovative drugs, first generic drugs, etc.
-
In July, executives of pharmaceutical companies set off another wave of departures, and the industry environment is changing
Time of Update: 2022-08-15
On July 4, Xinmai Medical announced that the company's board of directors recently received a resignation report from deputy general manager Jin Guocheng .
On July 4, Xinmai Medical announced that the company's board of directors recently received a resignation report from deputy general manager Jin Guocheng .
-
Traditional Chinese medicine, CRO and other pharmaceutical sub-sectors pulled up, and Xintian Pharmaceuticals rose by the daily limit
Time of Update: 2022-08-15
Its business covers the whole chain of drug R&D and production, including drug discovery, pharmaceutical research, clinical trials, customized R&D and production, and registration application According to the data, Baicheng Pharmaceutical is a comprehensive pharmaceutical R&D enterprise with technology development as the core.
-
Changes in the traditional Chinese medicine sector, and many stocks such as Teyi Pharmaceutical and Essence Pharmaceuticals rose
Time of Update: 2022-08-15
followed suit [Pharmaceutical Network Pharmaceutical Stock Market] According to news on June 6, the traditional Chinese medicine sector moved up.
83%; the net profit attributable to shareholders of the listed company was about 127 million yuan, a year-on-year increase of 189.
-
The number of medical representatives is expected to decrease by more than 2 million, and the transformation is imminent
Time of Update: 2022-08-15
It is necessary to return to academic promotion and continuously improve their professional capabilities in order to continue to face competition and seize new opportunities The industry believes that the medical representatives who choose to remain will face greater pressure, and the transformation is imminent.
-
Affected by favorable policies, traditional Chinese medicine may become the main line of investment in the second half of the year
Time of Update: 2022-08-15
It is worth noting that the industry as a whole continues to Under the positive development, the traditional Chinese medicine sector has also significantly outperformed the pharmaceutical sector in the past year and a half, with a cumulative increase of over 26% (data source: WIND, data from January 1, 2021 to June 30, 2022) .
-
The growth of investment and financing in the medical and health sector has slowed down, but these areas will still receive attention
Time of Update: 2022-08-15
2 billion yuan According to statistics, in the first half of 2022, there have been 632 investment and financing events in the medical and health sector nationwide, and the disclosed investment and financing amount is 115.
-
The pharmaceutical industry has set off a wave of AI research and development, and it will also have great prospects in the pharmaceutical field
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] With the help of AI pharmaceuticals, it can improve the speed of new drug research and development and reduce costs, and help pharmaceutical companies to spee
-
The development of traditional Chinese medicine welcomes the policy "bonus period", and the industry recommends paying attention to these two main investment lines
Time of Update: 2022-08-15
. Traditional Chinese medicine welcomes the "bonus period" of the policy, and the industry recommends paying attention to two main lines (Source: Pharmaceutical Network) For example, on July 14, Dong'e Ejiao issued an announcement on the pre-increase in the first half of 2022, and the net profit is expected to be 270 million yuan to 3.
-
This pharmaceutical stock has achieved 4 daily limits in a row, and has 253 subsidiaries by the end of 2021
Time of Update: 2022-08-15
. During the period, the company's performance also experienced rapid growth, but in 2019, Ruikang Pharmaceutical achieved a net profit of -928 million yuan attributable to the parent, a sharp drop of 220.
-
The number of license outs continues to grow, and multinational pharmaceutical companies become a great help for domestic innovative drugs to go overseas
Time of Update: 2022-08-15
Research, development, manufacturing and commercialization outside of China (China includes Mainland China, Hong Kong, Macau and Taiwan) For example, on August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022.
-
The development of traditional Chinese medicine continues to improve, and the pharmaceutical equipment of traditional Chinese medicine is constantly changing to "intelligent manufacturing"!
Time of Update: 2022-08-15
It will help more and more enterprises to achieve more efficient production With the development and application of new technologies such as the Internet of Everything, big data, and artificial intelligence, the positive shift to "intelligent manufacturing" brings more imagination to the traditional Chinese medicine industry.
-
Pharmaceutical CDMO maintains a high growth trend, and the domestic market size may reach 57.9 billion yuan in 2022
Time of Update: 2022-08-15
9 billion yuan, and the global pharmaceutical CDMO industry market scale will reach 106.
4 billion in 2020, with a compound annual growth rate of nearly 12% According to statistics, the market size of the global pharmaceutical CDMO industry has grown from US$35.
